Loading clinical trials...

Residual Plasma Concentration of Sorafenib and Adverse Events in CHC | Clinical Trials | Clareo Health

UNKNOWNNCT03340636

Residual Plasma Concentration of Sorafenib and Adverse Events in CHC

To date, Sorafenib is the only drug therapy to have demonstrated a benefit in overall survival in patients with advanced or metastatic hepatocellular carcinoma. However, this treatment causes many adv...

Lead sponsor: University Hospital, Caen•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment60

Start dateJan 2018

Last updatedNov 13, 2017

Condition

Advanced or Metastatic Hepatocellular Carcinoma

Locations shown

Caen University Hospital

Caen

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 13, 2017Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions